Effects of aspirin responsiveness and platelet reactivity on early vein graft thrombosis after coronary artery bypass graft surgery

Journal of the American College of Cardiology

Volumn 57, Issue 9, 2011, Pages 1069-1077

  Gluckman, Tyler J ^a   McLean, Rhondalyn C ^a   Schulman, Steven P ^a   Kickler, Thomas S ^a   Shapiro, Edward P ^a   Conte, John V ^a   McNicholas, Kathleen W ^b   Segal, Jodi B ^a   Rade, Jeffrey J ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Christiana Research Institute   (United States)

Author keywords

aspirin; platelet; thrombosis; thromboxane; vein graft

Indexed keywords

11 DEHYDRO THROMBOXANE B2; ACETYLSALICYLIC ACID; CREATININE; THROMBOXANE B2; UNCLASSIFIED DRUG;

ADULT; AGED; ANALYZER; ARTICLE; BLOOD VESSEL DIAMETER; COMPUTED TOMOGRAPHIC ANGIOGRAPHY; CORONARY ARTERY BYPASS GRAFT; DRUG EFFECT; FEMALE; GRAFT OCCLUSION; GRAFT PATENCY; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; RISK FACTOR; SAPHENOUS VEIN GRAFT; THROMBOCYTE AGGREGATION; THROMBOSIS; TREATMENT RESPONSE;

AGED; ASPIRIN; CORONARY ANGIOGRAPHY; CORONARY ARTERY BYPASS; FEMALE; FOLLOW-UP STUDIES; GRAFT OCCLUSION, VASCULAR; HUMANS; MALE; MIDDLE AGED; PLATELET ACTIVATION; PLATELET AGGREGATION INHIBITORS; PLATELET COUNT; SAPHENOUS VEIN; TIME FACTORS; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 79951992654     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2010.08.650     Document Type: Article

References (32)

1. J.G. Motwani, and E.J. Topol Aortocoronary saphenous vein graft disease Circulation 97 1998 916 931
2. G.M. FitzGibbons, H.P. Kafka, A.J. Leach, W.J. Keon, G.D. Hooper, and J.R. Burton Coronary bypass graft fate and patient outcome: angiographic follow-up of 5,065 grafts related to survival and reoperation in 1,388 patients during 25 years J Am Coll Cardiol 28 1996 616 626 (Pubitemid 26288642)
3. A.R. Halabi, J.H. Alexander, and L.K. Shaw Relation of early saphenous vein graft failure to outcomes following coronary artery bypass surgery Am J Cardiol 96 2005 1254 1259 (Pubitemid 41505404)
4. Antiplatelet Trialists' Collaboration Collaborative overview of randomised trials of antiplatelet therapy: II Maintenance of vascular graft or arterial patency by antiplatelet therapy Br Med J 308 1994 168
5. C. Patrono, and B. Rocca Drug insight: aspirin resistancefact or fashion? Nat Clin Pract Cardiovasc Med 4 2007 42 50 (Pubitemid 44971071)
6. C. Patrono Aspirin resistance: definition, mechanisms and clinical read-outs J Thromb Haemost 1 2003 1710 1713
7. G. Krasopoulos, S.J. Brister, W.S. Beattie, and M.R. Buchanan Aspirin "resistance" and risk of cardiovascular morbidity: systematic review and meta-analysis Br Med J 336 2008 195 198 (Pubitemid 351212675)
8. J.W. Eikelboom, G.J. Hankey, and J. Thom Incomplete inhibition of thromboxane biosynthesis by acetylsalicylic acid Determinants and effect on cardiovascular risk Circulation 118 2008 1690
9. J.W. Eikelboom, J. Hirsh, J.I. Weitz, M. Johnston, Q. Yi, and S. Yusuf Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events Circulation 105 2002 1650 1655 (Pubitemid 34298607)
10. N. Zimmermann, A. Wenk, and U. Kim Functional and biochemical evaluation of platelet aspirin resistance after coronary artery bypass surgery Circulation 108 2003 542 547 (Pubitemid 36961167)
11. N. Zimmermann, P. Kienzle, and A.A. Weber Aspirin resistance after coronary artery bypass grafting J Thorac Cardiovasc Surg 121 2001 982 984
12. T.J. Gluckman, J.B. Segal, and S.P. Schulman Effect of anti-platelet factor-4/heparin antibody induction on early saphenous vein graft occlusion after coronary artery bypass surgery J Thromb Haemost 7 2009 1457 1464
13. S.M. Nazarian, J.B. Thompson, and T.J. Gluckman Clinical and laboratory factors associated with shear-dependent platelet hyper-reactivity in patients on chronic aspirin therapy Thromb Res 126 2010 379 383
14. A.D. Michelson, A.L. Frelinger III, and M.I. Furman Current options in platelet function testing Am J Cardiol 98 2006 4N 10N
15. G.A. Fritsma, G.E. Ens, M.A. Alvord, A.A. Carroll, and R. Jensen Monitoring the antiplatelet action of aspirin 572 JAAPA 14 2001
16. V.O. Bjork, S. Ekestrom, A. Henze, T. Ivert, and C. Landou Early and late patency of aortocoronary vein grafts Scand J Thorac Cardiovasc Surg 15 1981 11 21 (Pubitemid 11154161)
17. M.A. Paz, J. Lupon, X. Bosch, J.L. Pomar, G. Sanz GESIC Study Group. Predictors of early saphenous vein aortocoronary bypass graft occlusion Ann Thorac Surg 56 1993 1101 1106 (Pubitemid 23337599)
18. P.J. Shah, I. Gordon, and J. Fuller Factors affecting saphenous vein graft patency: clinical and angiographic study in 1402 symptomatic patients operated on between 1977 and 1999 J Thorac Cardiovasc Surg 126 2003 1972 1977 (Pubitemid 38020761)
19. J.H. Alexander, G. Hafley, and R.A. Harrington Efficacy and safety of edifoligide, an E2F transcription factor decoy, for prevention of vein graft failure following coronary artery bypass graft surgery: PREVENT IV: a randomized controlled trial JAMA 294 2005 2446 2454 (Pubitemid 41627922)
20. E.H. Awtry, and J. Loscalzo Aspirin Circulation 101 2000 1206 1218 (Pubitemid 30146625)
21. A.L. Frelinger III, Y. Li, and M.D. Linden Association of cyclooxygenase-1-dependent and -independent platelet function assays with adverse clinical outcomes in aspirin-treated patients presenting for cardiac catheterization Circulation 120 2009 2586 2596
22. F.M. Pulcinelli, S. Riondino, and A. Celestini Persistent production of platelet thromboxane A2 in patients chronically treated with aspirin J Thromb Haemost 3 2005 2784 2789 (Pubitemid 41819808)
23. G. Davi, A. Falco, and C. Patrono Determinants of F2-isoprostane biosynthesis and inhibition in man Chem Phys Lipids 128 2004 149 163 (Pubitemid 38167384)
24. X. Hou, L.J. Roberts, and D.F. Taber 2,3-Dinor-5,6-dihydro-15-F(2t)- isoprostane: a bioactive prostanoid metabolite Am J Physiol Regul Integr Comp Physiol 281 2001 R391 R400
25. C.P. Hayward, P. Harrison, M. Cattaneo, T.L. Ortel, and A.K. Rao Platelet function analyzer (PFA)-100 closure time in the evaluation of platelet disorders and platelet function J Thromb Haemost 4 2006 312 319
26. E.J. Favaloro Clinical application of the PFA-100 Curr Opin Hematol 9 2002 407 415
27. J.L. Reny, P. de Moerloose, M. Dauzat, and P. Fontana Use of the PFA-100 closure time to predict cardiovascular events in aspirin-treated cardiovascular patients: a systematic review and meta-analysis J Thromb Haemost 6 2008 444 450 (Pubitemid 351280111)
28. M. Crescente, A. Di Castelnuovo, L. Iacoviello, G. De Gaetano, and C. Cerletti PFA-100 closure time to predict cardiovascular events in aspirin-treated cardiovascular patients: a meta-analysis of 19 studies comprising 3,003 patients Thromb Haemost 99 2008 1129 1131 (Pubitemid 351810502)
29. T. Chakroun, G. Gerotziafas, and F. Robert In vitro aspirin resistance detected by PFA-100 closure time: pivotal role of plasma von Willebrand factor Br J Haematol 124 2004 80 85 (Pubitemid 38021626)
30. M. Frossard, I. Fuchs, and J.M. Leitner Platelet function predicts myocardial damage in patients with acute myocardial infarction Circulation 110 2004 1392 1397 (Pubitemid 39238016)
31. P. Harrison, I. Mackie, and A. Mathur Platelet hyper-function in acute coronary syndromes Blood Coagul Fibrinolysis 16 2005 557 562 (Pubitemid 41658974)
32. I. Fuchs, M. Frossard, A. Spiel, E. Riedmuller, A.N. Laggner, and B. Jilma Platelet function in patients with acute coronary syndrome (ACS) predicts recurrent ACS J Thromb Haemost 4 2006 2547 2552 (Pubitemid 44741545)